| Texto completo | |
| Autor(es): |
Durymanova Ono, Ekaterina Alexandrovna
;
Taniwaki, Sueli Akemi
;
Brandao, Paulo
Número total de Autores: 3
|
| Tipo de documento: | Artigo Científico |
| Fonte: | Brazilian Journal of Microbiology; v. 48, n. 3, p. 566-569, JUL-SEP 2017. |
| Citações Web of Science: | 0 |
| Resumo | |
Abstract The aim of this study was to assess the in vitro and in vivo effects of short-interfering RNAs (siRNAs) against rabies virus phosphoprotein (P) mRNA in a post-infection treatment for rabies as an extension of a previous report (Braz J Microbiol. 2013 Nov 15;44(3):879-82). To this end, rabies virus strain RABV-4005 (related to the Desmodus rotundus vampire bat) were used to inoculate BHK-21 cells and mice, and the transfection with each of the siRNAs was made with Lipofectamine-2000™. In vitro results showed that siRNA 360 was able to inhibit the replication of strain RABV-4005 with a 1 log decrease in virus titter and 5.16-fold reduction in P mRNA, 24 h post-inoculation when compared to non-treated cells. In vivo, siRNA 360 was able to induce partial protection, but with no significant difference when compared to non-treated mice. These results indicate that, despite the need for improvement for in vivo applications, P mRNA might be a target for an RNAi-based treatment for rabies. (AU) | |
| Processo FAPESP: | 11/00439-7 - Silenciamento gênico pós-transcricional por interferência por RNA (RNAi) como terapia antiviral para a raiva |
| Beneficiário: | Ekaterina Alexandrovna Durymanova Ono |
| Modalidade de apoio: | Bolsas no Brasil - Doutorado |
| Processo FAPESP: | 13/05884-4 - Silenciamento gênico pós-transcricional por interferência por RNA (RNAi) como terapia antiviral para a raiva |
| Beneficiário: | Paulo Eduardo Brandão |
| Modalidade de apoio: | Auxílio à Pesquisa - Regular |